Articles
25.10.2021
Hazard ratio and HTA agencies

In oncology, a hazard ratio (HR) is commonly used to estimate the treatment effect for survival endp...

Read more
Articles
20.10.2021
The QALY shortfall

The QALY Shortfall aims to capture and recognise disease severity by assessing the degree of quality...

Read more
Articles
11.10.2021
The product life cycle

An overview of the product life cycle. The product life cycle must be managed efficiently to generat...

Read more
Articles
06.10.2021
PMA Perspective Q3 2021

Insights from pharmaceuticals, market access and Team Remap Q3 2021.

Read more
Articles
04.10.2021
Good value propositions

We outline the 3 key components of a good value proposition, designed to demonstrate the value of ne...

Read more
Articles
27.09.2021
Access for rare disease treatments

Innovative therapies for rare diseases may only be available in a select number of countries in Euro...

Read more
Articles
22.09.2021
Commercial arrangements in access to medicine

The introduction of new medicines in England requires the cooperation of industry and the NHS.

Read more
Articles
20.09.2021
Improving patient engagement

NICE is increasing opportunities for patient engagement by simplifying the process and increasing pa...

Read more
Articles
06.09.2021
Strategies to navigate patent expiry

Patents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...

Read more
Articles
06.09.2021
Real world evidence

Real-world evidence (RWE) refers to clinical and economic evidence which has been derived from the a...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.